Pyruvate inhibits growth of mammary adenocarcinoma 13762 in rats.
The growth of implanted mammary adenocarcinoma 13762 was measured in rats consuming a liquid diet (35% fat, 18% protein, 47% carbohydrate) supplemented with pyruvate (37.3 g/liter; n = 13) or maltose-dextrin (placebo; n = 13) for 21 days. Mean tumor diameter, measured on day 11, 14, 18, and 21 subsequent to tumor implantation, was 41, 32, 21, and 19% smaller in the pyruvate group (P < 0.05). When euthanized, tumor weight was also smaller in the pyruvate group: pyruvate = 15.0 +/- 2.3 (SEM) g; placebo = 24.9 +/- 3.2 g, P < 0.05. Visual inspection of organs suggested decreased lung metastases with pyruvate feeding (P < 0.05). Upon microscopic evaluation of organs, hepatic tumor was found only in the placebo group. We conclude that pyruvate inhibits implanted tumor growth in rats.
Stanko
R T
RT
Department of Medicine, Montefiore University Hospital, University of Pittsburgh Medical Center, Pennsylvania 15213-2582.
Mullick
P
P
Clarke
M R
MR
Contis
L C
LC
Janosky
J E
JE
Ramasastry
S S
SS
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D000818:Animals; D004249:DNA Damage; D005260:Female; D005609:Free Radicals; D008175:Lung Neoplasms / Q000556:secondary; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011773:Pyruvates / Q000494:pharmacology / Q000627:therapeutic use*; D019289:Pyruvic Acid; D051381:Rats; D011916:Rats, Inbred F344
D005609:Free Radicals; D011773:Pyruvates; D019289:Pyruvic Acid